GW Pharma (GWPH) Tops Q3 EPS by 103c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/4/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- AppLovin shares fall after court denies request against Unity
Cowen Reiterates Bullish View on GW Pharma (GWPH) Post Q3; Says All Eyes on Epilepsy Pivotal Data In Early Q1:16
August 6, 2015 1:30 PM EDTCowen analyst Phil Nadeau reiterated an Outperform rating and $135 price target on GW Pharma (NASDAQ: GWPH) following Q3 results although all eyes are on the epilepsy pivotal data in early Q1 2016.
Nadeau commented, "GW remains well funded with £254MMin cash at the... More
GW Pharma (GWPH) Announces Receipt of FDA Fast-Track Designation for CBD as NHIE Treatment
August 6, 2015 6:46 AM EDTGW Pharma (NASDAQ: GWPH) announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for a proprietary intravenous form of cannabidiol (CBD) to treat Neonatal Hypoxic-Ischemic Encephalopathy, or NHIE. In addition, the European Medicines Agency (EMA) has granted orphan designation for the same product to treat perinatal asphyxia, an alternate term that describes the same condition as NHIE, for which GW has already received Orphan Drug Designation from the FDA. There are currently no approved medicines in Europe or the U.S. specifically indicated for NHIE or perinatal... More
